Clinical predictors at diagnosis of disabling pediatric Crohn's disease
暂无分享,去创建一个
A. Duhamel | J. Salleron | G. Savoye | É. Lerebours | D. Turck | J. Colombel | M. Lémann | A. Cortot | V. Merle | C. Gower-Rousseau | J. Salomez | J. Dupas | G. Vernier-Massouille | M. Fumery | G. Vernier‐Massouille
[1] B. Abraham,et al. Disability in inflammatory bowel disease. , 2012, Gastroenterology clinics of North America.
[2] F. Vasseur,et al. Long‐term outcome of treatment with infliximab in pediatric‐onset Crohn's disease: A population‐based study , 2011, Inflammatory bowel diseases.
[3] David C Wilson,et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.
[4] J. Salleron,et al. Early Surgery is Not Associated With Poor Prognosis in Pediatric Crohn's Disease: A Population-Based Study , 2011 .
[5] A. Cieza,et al. Disability in Inflammatory Bowel Disease (IBD): Developing Icf Core Sets for Patients With IBD Based on the WHO International Classification of Functioning, Disability and Health , 2011 .
[6] M. Dubinsky,et al. Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease , 2011, Inflammatory bowel diseases.
[7] H. Tilg,et al. Development of the Crohn's disease digestive damage score, the Lémann score , 2010, Inflammatory bowel diseases.
[8] A. Zinsmeister,et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. , 2010, Gastroenterology.
[9] F. Vasseur,et al. Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study , 2010, The American Journal of Gastroenterology.
[10] J. Schölmerich,et al. Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data , 2010, The American Journal of Gastroenterology.
[11] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[12] L. Peyrin-Biroulet,et al. The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.
[13] P. Rutgeerts,et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.
[14] Andre Franke,et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] P. Lakatos,et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. , 2009, World journal of gastroenterology.
[16] S. Necozione,et al. Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] P. Rutgeerts,et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. , 2008, Gastroenterology.
[18] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[19] S. Targan,et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] Julia Salleron,et al. Natural history of pediatric Crohn's disease: a population-based cohort study. , 2008, Gastroenterology.
[21] C. Wijmenga,et al. Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort , 2008, Gut.
[22] A. Griffiths,et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease , 2008, Inflammatory bowel diseases.
[23] T. Molnár,et al. New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.
[24] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[25] J. Belaiche,et al. Predictors of severe Crohn's disease , 2008, Scandinavian journal of gastroenterology.
[26] M. Vatn,et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] K. Van Steen,et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.
[28] A. Griffiths,et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.
[29] S. Schreiber,et al. P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm , 2007 .
[30] A. Griffiths,et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[31] S. Dorn. Predictors of Crohn's disease. , 2006, Gastroenterology.
[32] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[33] E. Seidman,et al. Utility of Serological Markers in Predicting the Early Occurrence of Complications and Surgery in Pediatric Crohn's Disease Patients , 2006, The American Journal of Gastroenterology.
[34] K. Herrmann,et al. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis , 2006, Scandinavian journal of gastroenterology.
[35] S. Vermeire,et al. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease , 2005, Gut.
[36] P. Rutgeerts,et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. , 2005, Gastroenterology.
[37] A. Lacy,et al. Crohn's Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricturing Disease and Higher Rate of Surgical Recurrence , 2005, Annals of surgery.
[38] M. Bala,et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.
[39] A. Andriulli,et al. Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease—An IG-IBD Study , 2005, The American Journal of Gastroenterology.
[40] H. Drummond,et al. Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype , 2004, The American Journal of Gastroenterology.
[41] J. Ioannidis,et al. Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis , 2004, The American Journal of Gastroenterology.
[42] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[43] É. Lerebours,et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999) , 2004, Gut.
[44] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[45] Samir A. Shah,et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies , 2003, American Journal of Gastroenterology.
[46] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[47] Richard W. Martin,et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.
[48] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[49] R. Jian,et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy , 2002, American Journal of Gastroenterology.
[50] J. Belaiche,et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.
[51] F. T. Veloso,et al. Clinical Outcome of Crohn's Disease: Analysis According to the Vienna Classification and Clinical Activity , 2001, Inflammatory bowel diseases.
[52] Richard W. Martin,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.
[53] P. Rutgeerts,et al. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. , 1999, Gastrointestinal endoscopy.
[54] J. Colombel,et al. Incidence of inflammatory bowel disease in northern France (1988-1990). , 1994, Gut.
[55] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[56] G. Lichtenstein. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2008 .
[57] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[58] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[59] P. Rutgeerts,et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.
[60] S. Targan,et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. , 2002, Gastroenterology.